Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603.


Acute graft-versus-host diseases (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation (BMT). T helper 1 (Th1)-type cytokines such as interferon-gamma or tumor necrosis factor-alpha have been implicated in the pathogenesis of acute GVHD. TAK-603 is a new quinoline derivative, which is now in clinical trials for use as a disease-modifying antirheumatic drug. In preclinical studies, it inhibited delayed-type hypersensitivity, but not Arthus-type reaction, in mice, and selectively suppressed Th1 cytokine production. Thus, the present study was designed to investigate whether the Th1 inhibitor (TAK-603) ameliorates lethal acute GVHD in a mouse model. Administration of TAK-603 into BALB/c mice given 10 Gy total body irradiation followed by transplantation of bone marrow and spleen cells from C57BL/6 mice markedly reduced the mortality in association with minimal signs of GVHD pathology in the liver, intestine, and skin. TAK-603 reduced not only the production of Th1-type cytokines, but also the proportion of Th1 cells in CD4(+) helper T cells in this GVHD mouse model. These results suggest that TAK-603 could be a potent therapeutic agent for acute lethal GVHD.

Citations per Year

395 Citations

Semantic Scholar estimates that this publication has 395 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lu2001PreventionOL, title={Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603.}, author={Y. Lu and Saijun Sakamaki and H Kuroda and Toru Kusakabe and Yuichi Konuma and Taishin Akiyama and Akihito Fujimi and Naoaki Takemoto and Kiwami Nishiie and Takuya Matsunaga and Yoshiyuki Hirayama and Jun Kato and Shigeyuki Kon and Kazuhiko Kogawa and Yoshiro Niitsu}, journal={Blood}, year={2001}, volume={97 4}, pages={1123-30} }